Literature DB >> 9276373

Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system.

A L Zietman1, E A Prince, B M Nakfoor, J J Park.   

Abstract

PURPOSE: To test the relative effect of neoadjuvant and adjuvant androgen deprivation on the radiation response of an androgen dependent tumor. METHODS AND MATERIALS: The transplantable, androgen dependent, Shionogi adenocarcinoma was grown as allografts in the hind limbs of NCr/Sed (nu/nu) athymic nude mice. Bilateral orchiectomy was the chosen form of androgen deprivation. Groups of tumors were irradiated to graded tumor doses and then studied for durable tumor control. The radiation response was expressed as the radiation dose required to control 50% of the tumors (TCD50). The sequence of radiation and orchiectomy was studied.
RESULTS: When radiation was combined with orchiectomy the Shionogi tumor was significantly more likely to be controlled than when radiation was used alone. Orchiectomy 12 days prior to radiation (neoadjuvant therapy) produced a significantly greater decline in the TCD50 than when orchiectomy was used 1 day or 12 days after radiation (adjuvant therapy). If, before radiation, tumors were allowed to regrow after orchiectomy to their original size in an androgen independent fashion then the advantage was largely lost. Those tumors responding well to neoadjuvant orchiectomy (>50% volume decrease) were significantly more likely to be eradicated by radiation than those with a lesser response.
CONCLUSION: When using combinations of androgen deprivation and radiation in the treatment of the Shionogi tumor, sequence and timing of the therapies are crucial to maximize the effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276373     DOI: 10.1016/s0360-3016(97)00309-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

Review 1.  External beam radiation therapy: role of androgen deprivation.

Authors:  Patrick Kupelian
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

2.  Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review.

Authors:  A Dal Pra; F L Cury; L Souhami
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

3.  Radiation therapy in prostate cancer: a risk-adapted strategy.

Authors:  A J Hayden; C Catton; T Pickles
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

Review 4.  [Radiotherapy for locally advanced prostate cancer].

Authors:  K Herfarth; F Sterzing
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

Review 5.  Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.

Authors:  M Ghashghaei; M Kucharczyk; S Elakshar; T Muanza; T Niazi
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

6.  Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Authors:  Mack Roach; Jennifer Moughan; Colleen A F Lawton; Adam P Dicker; Kenneth L Zeitzer; Elizabeth M Gore; Young Kwok; Michael J Seider; I-Chow Hsu; Alan C Hartford; Eric M Horwitz; Kosj Yamoah; Christopher U Jones; Jeff M Michalski; W Robert Lee; Thomas M Pisansky; Rachel Rabinovitch; Marvin Rotman; Rodger M Pryzant; Harold E Kim; Charles R Thomas; William U Shipley; Howard M Sandler
Journal:  Lancet Oncol       Date:  2018-10-10       Impact factor: 41.316

Review 7.  Pharmacotherapeutic management of locally advanced prostate cancer: current status.

Authors:  Jarad M Martin; Stephane Supiot; Dominik R Berthold
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 8.  The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer.

Authors:  Tony Y Eng; Join Y Luh; Charles R Thomas
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 3.092

9.  Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective.

Authors:  Elizabeth C Kent; Maha Ha Hussain
Journal:  Rev Urol       Date:  2003

Review 10.  Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.

Authors:  Tanya B Dorff; L Michael Glode
Journal:  Curr Opin Urol       Date:  2013-07       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.